

ASX Announcement 25 February 2021

Resignation of Non-Executive Director – Dr Alan Dunton

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today advises that Non-Executive Director Dr Alan Dunton has resigned from the Company's Board, effective immediately.

Dr Dunton joined Regeneus as Non-Executive Director in April 2019 to support the Board in executing the Company's strategy to commercialise its lead stem cell technology platform Progenza™ in Japan. The Company has since moved closer to this goal with the signing of its licence and collaboration agreement with Japanese manufacturer Kyocera Corporation, to commercialise Progenza™ for the treatment of knee osteoarthritis in Japan.

Regeneus Chairman Barry Sechos said, "We thank Dr Dunton for the valuable contribution he has made since joining Regeneus' Board, during what has been a transformational period for the Company. We wish him all the best."

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications
T: (03) 8866 1200
E: WE-AURegeneus@we-worldwide.com